Validation of the Monocyte Activation Test Demonstrating Equivalence to the Rabbit Pyrogen Test
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262211136 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Luisa Burgmaier und 5 weiteren Autor:innen. Beteiligte Einrichtung: Microcoat Biotechnologie GmbH, Am Neuland 3, 82347 Bernried am Starnberger See, Germany. Hauptthemen laut MEDLINE: Pyrogens, Monocytes, Endotoxins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Monocyte Activation Test (MAT) is an in vitro assay that uses human blood cells to detect both endotoxins and non-endotoxin pyrogens (NEPs), representing a scientifically and ethically superior alternative to the in vivo Rabbit Pyrogen Test (RPT). In the European Pharmacopoeia (Ph. Eur.), the MAT is a compendial method which is explicitly recommended to replace the RPT, requiring only product-specific verification. In contrast, the United States Pharmacopeia (USP) lacks a dedicated MAT chapter, meaning the MAT can only be accepted as an alternative method, given that a full method validation according to USP is provided in addition to a product-specific verification. This study presents a two-tiered validation strategy addressing both regulatory frameworks: a generic (product-independent) validation aligned with the semi-quantitative test method according to Ph. Eur., ICH Q2, and USP followed by a product-specific verification. The generic validation consisted of the following parameters: Range and Linearity, Limit of Detection, Accuracy, Specificity, Precision, and Robustness. Robustness was extensively tested under routine-relevant conditions, including variation in the stimulation time, IL-6 read-out timing, freeze–thaw stability, and lot-to-lot comparability. Additionally, an equivalency study of the RPT and the MAT was performed. The data showed that the MAT is at least non-inferior if not superior to the RPT and met the requirements for successful FDA approval of the MAT as an alternative method for pyrogen testing. The MAT was successfully applied to several parenteral drug products. This work provides a transferable framework for GMP-compliant MAT implementation and supports broader international acceptance of the method as a replacement for the RPT in pharmaceutical quality control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Microcoat Biotechnologie GmbH, Am Neuland 3, 82347 Bernried am Starnberger See, Germany.
- Department of Thoracic and Cardiovascular Surgery, University Hospital Tuebingen, Calwerstr. 7/1, 72076 Tuebingen, Germany.
- Roche Diagnostics GmbH, Sandhofer Str. 116, 68305 Mannheim, Germany.
- Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
ORCID-Profile: Johannes Reich
Zitieren
APA
Burgmaier, L., van den Berg, J., Gajewi, M., Röder, R., Reich, J., & Deutschmann, S. M. (2025). Validation of the Monocyte Activation Test Demonstrating Equivalence to the Rabbit Pyrogen Test. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262211136
Vancouver
Burgmaier L, van den Berg J, Gajewi M, Röder R, Reich J, Deutschmann SM. Validation of the Monocyte Activation Test Demonstrating Equivalence to the Rabbit Pyrogen Test. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262211136
BibTeX
@article{Burgmaier2025,
author = {Burgmaier, Luisa and van den Berg, Jonas and Gajewi, Maria and Röder, Ruth and Reich, Johannes and Deutschmann, Sven M},
title = {Validation of the Monocyte Activation Test Demonstrating Equivalence to the Rabbit Pyrogen Test},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262211136}
}
EUVIMED